title: Review of the economic evaluations of hormonal therapy for patients with locally advanced prostate cancer.
abstract: Androgen deprivation therapy (ADT) is used as first-line therapy for locally advanced or metastatic prostate cancer aiming to reduce testosterone to castrate levels. The authors present an overview of the existing cost-effectiveness studies of ADT in prostate cancer. Cost-effectiveness of ADT was reviewed using a systematic search of the peer-reviewed literature, as well as research abstracts presented at various scientific and industry meetings. Most cost-effectiveness analyses of ADT reported results within the accepted societal threshold of US$50,000 cost/quality-adjusted life year needed to adopt new technology.
authors.affiliation: Hind T Hatoum & Company, 155 N Harbor Drive, 1912, Chicago, IL 60601, USA. hthatoum@sbcglobal.net
authors.forename: Hind T
authors.initials: HT
authors.lastname: Hatoum
authors.forename: E David
authors.initials: ED
authors.lastname: Crawford
authors.forename: Sandy Kildegaard
authors.initials: SK
authors.lastname: Nielsen
authors.forename: Swu-Jane
authors.initials: SJ
authors.lastname: Lin
authors.forename: Dennis C
authors.initials: DC
authors.lastname: Marshall
mesh_terms: D000726:Androgen Antagonists / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000191:economics / Q000473:pathology; D019057:Quality-Adjusted Life Years; D013739:Testosterone / Q000378:metabolism*
chemical_list: D000726:Androgen Antagonists; D013739:Testosterone